Strict Tysabri Risk Management Plan Drives Panel Support For Crohn’s

A highly restrictive risk management program for Biogen Idec/Elan's Tysabri swayed a joint advisory panel to recommend the product's approval for a Crohn's disease indication July 31 despite modest efficacy data and remaining safety concerns

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet